Pilot trial suggests structured support may help limit weight regain after GLP-1 treatment

A pilot trial suggests that structured support may help limit weight regain after treatment with glucagon-like peptide-1 (GLP-1) receptor agonists, which are effective for obesity but often lead to rapid weight regain upon discontinuation. The trial, published in Obesity Science & Practice, indicates that such support may attenuate early weight gain after stopping GLP-1 treatment.